Upfront, AbbVie will pay Regenexbio $370 million for rights to RGX-314, an experimental gene therapy for the treatment of progressive retinal ...
https://www.google.com/url?rct=j&sa=t&url=https://www.nasdaq.com/articles/why-regenxbio-stock-is-way-up-today-2021-09-13&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNHFg0KtPvHYT9VLea80qLy5ZIKLoA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.